HGB

EQS-News: Baader Bank posts positive consolidated pre-tax result and continued invest-ment and growth for HY1 2023

Retrieved on: 
Thursday, July 27, 2023

At EUR 20.0 million, the result from trading business shows a significant decline compared to the first quarter of the previous year (HY1 2022: EUR 39.8 million).

Key Points: 
  • At EUR 20.0 million, the result from trading business shows a significant decline compared to the first quarter of the previous year (HY1 2022: EUR 39.8 million).
  • Accordingly, total income amounted to EUR 83.5 million in the first half year (HY1 2022: EUR 84.8 million), down 2% on the reference period.
  • Total expenses in the first half year of 2023 increased noticeably by 9 % to EUR 80.6 million (HY1 2022: EUR 73.8 million).
  • Provision expenses of EUR 3.5 million (HY1 2022: EUR 4.9 million) include allocations to the fund for general banking risks of EUR 6.1 million (HY1 2022: EUR 8.7 million).

EQS-News: Smartbroker Holding AG: Audited consolidated financial statements confirm preliminary figures from March – SMARTBROKER+ market launch imminent

Retrieved on: 
Thursday, July 20, 2023

Despite the difficult market environment, group sales amounted to €52.8 million (preliminary: €52.6 million); EBITDA of €8.8 million (preliminary: approx.

Key Points: 
  • Despite the difficult market environment, group sales amounted to €52.8 million (preliminary: €52.6 million); EBITDA of €8.8 million (preliminary: approx.
  • Despite the challenging market environment, the Smartbroker Group achieved important milestones on the way to the relaunch of its online broker Smartbroker.
  • The transaction business, of which Smartbroker is by far the largest source of revenue, contributed almost €19 million to the group's turnover.
  • The focus is on the imminent market launch of SMARTBROKER+ and the subsequent migration of the existing Smartbroker customers to the new platform.

EQS-News: Traumhaus AG reports audited figures for 2022

Retrieved on: 
Saturday, June 10, 2023

The preliminary consolidated sales reported by Traumhaus AG (ISIN: DE000A2NB7S2) on March 30, 2023 for the past 2022 financial year, can be confirmed at EUR 72.4 million (preliminary reported figures: EUR 72.5 million; previous year: EUR 102.2 million).

Key Points: 
  • The preliminary consolidated sales reported by Traumhaus AG (ISIN: DE000A2NB7S2) on March 30, 2023 for the past 2022 financial year, can be confirmed at EUR 72.4 million (preliminary reported figures: EUR 72.5 million; previous year: EUR 102.2 million).
  • Total output including other operating income fell slightly to EUR 115.7 million (previous year: EUR 116.4 million).
  • Group EBITDA amounts to EUR 4.9 million (preliminary reported figures: EUR 4.9 million; previous year EUR 13.1 million).
  • Otfried Sinner, CEO of Traumhaus AG: “2022 was a very challenging year for the entire real estate.

EQS-News: ​​​​​​​Daldrup & Söhne AG increases EBIT by 12.5 % in 2022

Retrieved on: 
Friday, June 2, 2023

The EBIT margin, based on total operating performance, was thus 5.0 % (3.4 %), in line with the forecast issued for the year under review (4 to 6 %).

Key Points: 
  • The EBIT margin, based on total operating performance, was thus 5.0 % (3.4 %), in line with the forecast issued for the year under review (4 to 6 %).
  • As already communicated, the Group's total operating performance of EUR 36.9 million was around EUR 5 million below the original forecast.
  • Daldrup & Söhne AG has successfully continued its path of financial and operational consolidation in 2022.
  • Daldrup & Söhne AG's business model is largely independent of economic cycles and characterized by a long-term order environment for public services.

EQS-News: Enapter AG: Final figures for fiscal year 2022 published

Retrieved on: 
Tuesday, May 2, 2023

Berlin (May 02, 2023); Enapter AG (ISIN:DE000A255G02) has published its final figures for the fiscal year 2022 and achieved a record year in terms of sales in the past fiscal year.

Key Points: 
  • Berlin (May 02, 2023); Enapter AG (ISIN:DE000A255G02) has published its final figures for the fiscal year 2022 and achieved a record year in terms of sales in the past fiscal year.
  • According to final and audited figures (HGB), Enapter generated revenues of EUR 14.7 million, compared to EUR 8.4 million in the previous year.
  • EBITDA amounted to -10.6 million euros (previous year: -7.6 million euros) and the net result for the year to -13.0 million euros (previous year: -8.7 million euros).
  • Enapter has set an important strategic course for its long-term growth in 2022.

EQS-News: Baader Bank posts positive consolidated pre-tax result and continued growth for Q1 2023

Retrieved on: 
Friday, April 28, 2023

At EUR 13.7 million, the result from trading business shows a significant decline compared to the first quarter of the previous year (Q1 2022: EUR 33.1 million).

Key Points: 
  • At EUR 13.7 million, the result from trading business shows a significant decline compared to the first quarter of the previous year (Q1 2022: EUR 33.1 million).
  • Accordingly, total income amounted to EUR 47.1 million in the first quarter (Q1 2022: EUR 57.0 million), down 17% on the strong comparative quarter.
  • Total expenses in the first quarter of 2023 decreased slightly by 3 % to EUR 45.3 million (Q1 2022: EUR 46.7 million).
  • This includes allocations to the fund for general banking risks of EUR 6.1 million (Q1 2022: EUR 9.7 million).

EQS-News: Formycon publishes results for financial year 2022

Retrieved on: 
Friday, April 28, 2023

The annual report at Group level is published for the first time in accordance with IFRS (International Financial Reporting Standards).

Key Points: 
  • The annual report at Group level is published for the first time in accordance with IFRS (International Financial Reporting Standards).
  • Furthermore, a toxicity study has been initiated, which results are a prerequisite for entering the clinical development phase.
  • On December 31, 2022, the Formycon Group's financial figures had developed as follows: Group revenues, which in addition to Formycon AG also include the fully consolidated subsidiaries Formycon Project 201 GmbH, FYB202 Project GmbH, Formycon Project 203 GmbH, Bioeq GmbH and the 50% stake in Bioeq AG increased to a total of Euro 42.5 million (2021 IFRS: Euro 36.6 million) in the fiscal year 2022.
  • Formycon AG achieved revenues (HGB) of Euro 28.3 million in the financial year 2022 (2021 HGB: Euro 26.5 million).

EQS-News: InCity Immobilien AG: WITH A CONSOLIDATED LOSS OF EUR 2.9 M ACC. TO HGB, INCITY’S ON TARGET FOR 2022 – CONTINUED HIGH HIDDEN RESERVES IN THE PORTFOLIO

Retrieved on: 
Friday, April 28, 2023

TO HGB, INCITY’S ON TARGET FOR 2022 – CONTINUED HIGH HIDDEN RESERVES IN THE PORTFOLIO

Key Points: 
  • TO HGB, INCITY’S ON TARGET FOR 2022 – CONTINUED HIGH HIDDEN RESERVES IN THE PORTFOLIO
    The issuer is solely responsible for the content of this announcement.
  • TO HGB, INCITY’S ON TARGET FOR 2022 – CONTINUED HIGH HIDDEN RESERVES IN THE PORTFOLIO
    Schönefeld, 27 April 2022 – The annual report of InCity Immobilien AG (“InCity AG”) published today reports a net loss (acc.
  • to HGB) of EUR 2.9 m at Group level and a net loss of EUR 1.9 m at single-entity annual financial statement level for fiscal year 2022.
  • These amounted to approximately EUR 6.9 m after around EUR 6.7 m in the prior year.

EQS-News: action press AG: Fiscal year 2022: Preliminary annual results for 2022, restructuring of the group fully completed, slight increase in sales, synergy effects to take effect from 2023 onwards

Retrieved on: 
Wednesday, April 26, 2023

action press AG: Fiscal year 2022: Preliminary annual results for 2022, restructuring of the group fully completed, slight increase in sales, synergy effects to take effect from 2023 onwards

Key Points: 
  • action press AG: Fiscal year 2022: Preliminary annual results for 2022, restructuring of the group fully completed, slight increase in sales, synergy effects to take effect from 2023 onwards
    The issuer is solely responsible for the content of this announcement.
  • This was primarily due to profit transfers and group allocations with the two subsidiaries action press international GmbH and ddp media GmbH.
  • As much as 2022 went as expected, the synergy effects of the reorganization are having an impact: so far, fiscal 2023 has been profitable.
  • With around 160 million photos (as of October 2022), action press is one of the largest image databases in the world.

Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Retrieved on: 
Tuesday, April 25, 2023

To date, all patients have received only the lowest subcutaneous dose of OMS906 in this multidose trial.

Key Points: 
  • To date, all patients have received only the lowest subcutaneous dose of OMS906 in this multidose trial.
  • This single-arm, open-label clinical trial is evaluating the effect of once-monthly subcutaneous administration of OMS906 in patients with PNH.
  • OMS906 is Omeros’ lead investigational humanized monoclonal antibody targeting MASP-3, the key and most upstream activator of the alternative pathway of complement.
  • “We are excited by the data resulting from this trial of treatment-naïve patients,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.